Skip to main content
. 2015 Mar 23;33(18):2013–2020. doi: 10.1200/JCO.2014.58.1041

Fig 2.

Fig 2.

Computed tomography scans showing partial response in primary tumor of metastatic renal cell carcinoma in patient treated with nivolumab; 48-year-old patient with low-volume but poorly differentiated disease who developed progressive disease after sunitinib, sorafenib, and thoracic surgery achieved partial response in primary tumor (indicated by arrows) after treatment with nivolumab 1 mg/kg. Treatment was held after three cycles, and response continued for 3 years after therapy.